BRPI0911673A2 - tratamento de infecções pelo vírus da hepatite c com telaprevir (vx-950) em pacientes não responsivos ao tratamento com interferon-alfa-2a/2b peguilado e ribavirin - Google Patents

tratamento de infecções pelo vírus da hepatite c com telaprevir (vx-950) em pacientes não responsivos ao tratamento com interferon-alfa-2a/2b peguilado e ribavirin

Info

Publication number: BRPI0911673A2
Authority: BR; Brazil
Prior art keywords: treatment; telaprevir; ribavirin; hepatitis; interferon alfa
Prior art date: 2008-04-23

Application number

BRPI0911673A

Other languages

English (en)

Inventor

Jacobson Ira

Mchutchison John

Mcnair Lindsay

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-23

Filing date

2009-04-23

Publication date

2017-12-05

2009-04-23 Application filed by Vertex Pharma filed Critical Vertex Pharma

2017-12-05 Publication of BRPI0911673A2 publication Critical patent/BRPI0911673A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0911673A 2008-04-23 2009-04-23 tratamento de infecções pelo vírus da hepatite c com telaprevir (vx-950) em pacientes não responsivos ao tratamento com interferon-alfa-2a/2b peguilado e ribavirin BRPI0911673A2 (pt)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US4733608P	2008-04-23	2008-04-23
US6000808P	2008-07-30	2008-07-30
US9945208P	2008-09-23	2008-09-23
US10980508P	2008-10-30	2008-10-30
US15253509P	2009-02-13	2009-02-13
US16168109P	2009-03-19	2009-03-19
PCT/US2009/002526 WO2009131696A1 (en)	2008-04-23	2009-04-23	Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin

Publications (1)

Publication Number	Publication Date
BRPI0911673A2 true BRPI0911673A2 (pt)	2017-12-05

Family

ID=41066401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0911673A BRPI0911673A2 (pt)	2008-04-23	2009-04-23	tratamento de infecções pelo vírus da hepatite c com telaprevir (vx-950) em pacientes não responsivos ao tratamento com interferon-alfa-2a/2b peguilado e ribavirin

Country Status (14)

Country	Link
US (2)	US8664273B2 (pt)
EP (1)	EP2280709A1 (pt)
JP (1)	JP2011518825A (pt)
KR (1)	KR20110015568A (pt)
CN (1)	CN102083433A (pt)
AU (1)	AU2009238599A1 (pt)
BR (1)	BRPI0911673A2 (pt)
CA (1)	CA2722306A1 (pt)
EA (1)	EA201071230A1 (pt)
IL (1)	IL208726A0 (pt)
MX (1)	MX2010011580A (pt)
NZ (1)	NZ588655A (pt)
SG (1)	SG190569A1 (pt)
WO (1)	WO2009131696A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8399615B2 (en)	2005-08-19	2013-03-19	Vertex Pharmaceuticals Incorporated	Processes and intermediates
EP2396028A2 (en) *	2009-02-12	2011-12-21	Vertex Pharmceuticals Incorporated	Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
GB201103837D0 (en) *	2011-03-07	2011-04-20	Oxagen Ltd	Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
CA2811250C (en)	2011-10-21	2015-08-11	Abbvie Inc.	Methods for treating hcv
SE1450019A1 (sv)	2011-10-21	2014-01-10	Abbvie Inc	Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
EP3448392A4 (en)	2016-04-28	2020-01-15	Emory University	ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101068547A (zh) *	2004-10-29	2007-11-07	沃泰克斯药物股份有限公司	含有vx－950的剂型及其给药方案
MY141025A (en) *	2004-10-29	2010-02-25	Vertex Pharma	Dose forms
CN101489557B (zh) *	2006-02-27	2013-12-18	弗特克斯药品有限公司	包含vx-950的共晶体和包含所述共晶体的药物组合物

2009
- 2009-04-23 MX MX2010011580A patent/MX2010011580A/es active IP Right Grant
- 2009-04-23 CN CN2009801246684A patent/CN102083433A/zh active Pending
- 2009-04-23 BR BRPI0911673A patent/BRPI0911673A2/pt not_active IP Right Cessation
- 2009-04-23 SG SG2013030309A patent/SG190569A1/en unknown
- 2009-04-23 EP EP09735729A patent/EP2280709A1/en not_active Withdrawn
- 2009-04-23 CA CA2722306A patent/CA2722306A1/en not_active Abandoned
- 2009-04-23 JP JP2011506298A patent/JP2011518825A/ja active Pending
- 2009-04-23 WO PCT/US2009/002526 patent/WO2009131696A1/en not_active Ceased
- 2009-04-23 EA EA201071230A patent/EA201071230A1/ru unknown
- 2009-04-23 AU AU2009238599A patent/AU2009238599A1/en not_active Abandoned
- 2009-04-23 NZ NZ588655A patent/NZ588655A/xx not_active IP Right Cessation
2010
- 2010-04-23 KR KR1020107026162A patent/KR20110015568A/ko not_active Ceased
- 2010-10-14 IL IL208726A patent/IL208726A0/en unknown
2011
- 2011-06-03 US US13/153,199 patent/US8664273B2/en not_active Expired - Fee Related
2014
- 2014-01-16 US US14/156,596 patent/US20140127160A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2009238599A1 (en)	2009-10-29
WO2009131696A1 (en)	2009-10-29
MX2010011580A (es)	2010-11-09
KR20110015568A (ko)	2011-02-16
US8664273B2 (en)	2014-03-04
EP2280709A1 (en)	2011-02-09
EA201071230A1 (ru)	2011-06-30
US20140127160A1 (en)	2014-05-08
IL208726A0 (en)	2010-12-30
JP2011518825A (ja)	2011-06-30
SG190569A1 (en)	2013-06-28
US20120045415A1 (en)	2012-02-23
CA2722306A1 (en)	2009-10-29
NZ588655A (en)	2012-12-21
CN102083433A (zh)	2011-06-01

Publication	Publication Date	Title
BRPI0911673A2 (pt)	2017-12-05	tratamento de infecções pelo vírus da hepatite c com telaprevir (vx-950) em pacientes não responsivos ao tratamento com interferon-alfa-2a/2b peguilado e ribavirin
BRPI0918653A2 (pt)	2015-12-01	combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.
WO2009061395A3 (en)	2010-03-18	Hcv combination therapies comprising vx-950, peg-ifn and ribavirin
WO2010093843A3 (en)	2010-10-07	Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
HRP20070435A2 (hr)	2008-02-29	Triciklički nukleozidni spojevi za liječenje virusnih infekcija
BRPI0906710A2 (pt)	2015-08-04	Peptídeo derivado de pres modificado hidrofóbico de vírus da hepatite b (hbv) e seu uso como inibidores de entrada de hbv e hdv
CY1112848T1 (el)	2016-02-10	Αναστολεις του ιου της ηπατιτιδας c
DK2155758T3 (da)	2012-11-05	Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
DK1976516T3 (da)	2013-07-15	Behandling af viral hepatitis
BR112014006314A2 (pt)	2017-04-11	métodos para tratamento do vírus da hepatite c (hcv) compreendendo pelo menos dois agentes antivirais de atuação direta, ribavirina, sem interferon
EP2055329A4 (en)	2014-04-16	BLOOD TREATMENT FILTER AND BLOOD TREATMENT CIRCUIT
DK1981506T6 (da)	2021-06-14	Langtidsbehandling af hiv-infektion med tcm278
EP2536410A4 (en)	2013-10-09	Substituted pyridine and pyrimidine derivatives and their use in the treatment of viral infections
EP1999687A4 (en)	2010-12-15	EFFICIENT PROCESSING OF CONTENT WITHOUT FORMATTING IN A DIGITAL IMAGE
BRPI0811447A2 (pt)	2014-10-29	Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
EP1979472A4 (en)	2010-05-12	METABOLOMIC DETERMINATION IN ASSISTED REPRODUCTION TECHNOLOGY
IL183032A0 (en)	2007-10-31	Andrographolide derivatives to treat viral infections
BRPI0912570A2 (pt)	2016-04-26	anticorpos humanizados contra interferon-alfa humano
BRPI0823197A2 (pt)	2015-06-23	Anticorpos contra hepatite c e aplicações dos mesmos
BRPI0814363A2 (pt)	2015-01-27	Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos
EP2120988A4 (en)	2011-02-23	TREATMENT OF HEPATITIS C VIRUS INFECTIONS
DK2054050T3 (da)	2012-09-03	Behandling af brusksygdomme med FGF-18
IL210717A (en)	2017-07-31	Preparations for use in inhibiting dengue virus infection and increasing antibody-mediated dengue infection
ZA200904068B (en)	2012-09-29	Anti-tsg101 antibodies and their uses for treatment of viral infections
IL225861A (en)	2016-03-31	Indazole-3-carboxamide derivatives and their use in the preparation of c-viral hepatitis drugs

Legal Events

Date	Code	Title	Description
2017-12-19	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-04-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2018-05-02	B25B	Requested transfer of rights rejected	Owner name: VERTEX PHARMACEUTICALS INCORPORATED (US)